ASH 2018 | Factors influencing the outcomes of NHL patients after ASCT and cyclophosphamide
Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the report of the EBMT Lymphoma Working Party on the influence of donor type, stem cell source and conditioning regimen on the outcomes of lymphoma patients after haploidentical transplant and cyclophosphamide. Dr Sureda highlights how no donor-related factors were associated with the outcomes of this group, whereas disease status at the time of transplant, type of lymphoma and conditioning regimen did. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up